AMGN supply chain intelligence for Amgen Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Amgen's supply chain spans biologics manufacturing, drug development, distribution, licensing, and healthcare customer relationships. ChainSifter tracks verified public-company relationships for Amgen.
Use this AMGN supply chain page to inspect supplier, customer, and related biotech or pharmaceutical chain data.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| HBIO | Harvard Bioscience, Inc. | 92% | Reciprocal relationship from HBIO graph: Our pharmaceutical and biotechnology customers include companies and research laboratories such as Abbott, Amgen, AstraZeneca, Bayer, Glaxo Smith Kline, Johns… |
| PODD | Insulet Corporation | 92% | Reciprocal relationship from PODD graph: Substantially all of our Drug Delivery revenue consists of sales of pods to Amgen for use in the Neulasta ® Onpro ® kit, a delivery system for Amgen’s Neulast… |
| TCRX | TScan Therapeutics, Inc. | 92% | Reciprocal relationship from TCRX graph: The Company concluded that Amgen meets the definition of a customer, as the Company is delivering research and development activities and a license of intelle… |
| CTMX | CytomX Therapeutics, Inc. | 90% | Reciprocal relationship from CTMX graph: In September 2017, we entered into a Collaboration and License Agreement (the "Amgen Agreement") with Amgen. |
| ONC | BeOne Medicines AG | 90% | Reciprocal relationship from ONC graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ONC graph: For the three months ended March 31, 2026 and 2025, the Company’s other revenu… |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 80% | Reciprocal relationship from ARWR graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ARWR graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from ARWR g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | USGOV-DEPARTMENT-OF-HEALTH-AND-HUMAN-SERVICES | 95% | USAspending awards from Department of Health and Human Services: $26,408,674 across 1 awards. 75A50119C00061 THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC … |
| CTMX | CytomX Therapeutics, Inc. | 90% | Reciprocal relationship from CTMX graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from CTMX graph: In September 2017, we entered into a Collaboration and License Agreement (th… |
| CUZ | Cousins Properties Incorporated | 90% | Reciprocal relationship from CUZ graph: 14 Amgen 1 1 163,169 6,833 0.8% 3.8 |
| NAUT | Nautilus Biotechnology, Inc. | 90% | Reciprocal relationship from NAUT graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from NAUT graph: In October 2021, we entered into a research collaboration agreement with Amg… |
| NMRA | Neumora Therapeutics, Inc. | 90% | Reciprocal relationship from NMRA graph: Additionally, Amgen purchased 12.7 million shares of our Series A-2 Preferred Stock at a purchase price of $7.85 per share, for total consideration of $100.0 … |
| UNH | UnitedHealth Group Incorporated | 85% | Reciprocal relationship from UNH graph: Reciprocal relationship from AMGN graph: Reciprocal relationship from UNH graph: Reciprocal relationship from AMGN graph: ded December 31, 2025, Part I, Item 1… |
| UNITED-HEALTH-GROUP | UNITED-HEALTH-GROUP | 85% | ded December 31, 2025, Part I, Item 1A. Risk Factors —Concentration of sales at certain of our wholesaler distributors, and consolidation of private payers, such as insurers, and PBMs has negatively … |
| ONC | BeOne Medicines AG | 80% | Reciprocal relationship from ONC graph: The Company had committed capital related to the Amgen collaboration agreement |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| AMGN-DEBT | Debt stack $57.3B | 90% | Market cache reports total debt of $57.3B. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| AMGN-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC | VANGUARD CAPITAL MANAGEMENT LLC | 90% | 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 3134 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| NVSEF | Novartis AG | 100.00 | 2 | |
| ABBVIE | ABBVIE | 100.00 | 2 | |
| MRK | Merck & Co., Inc. | 100.00 | 2 | |
| MPLT | MapLight Therapeutics, Inc. | 100.00 | 2 | |
| SNYNF | Sanofi | 100.00 | 2 | |
| AMGEN | AMGEN | 100.00 | 2 | |
| NBP | NovaBridge Biosciences | 100.00 | 2 | |
| NVS | Novartis AG | 100.00 | 2 | |
| BDX | Becton, Dickinson and Company | 100.00 | 2 | |
| TCRX | TScan Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| ABBV | AbbVie Inc. | 100.00 | 2 | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | 100.00 | 1 | ['supplier'] |
| PODD | Insulet Corporation | 100.00 | 1 | ['supplier'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 2 | |
| LAB | Standard BioTools Inc. | 100.00 | 2 | |
| UNH | UnitedHealth Group Incorporated | 100.00 | 1 | ['customer'] |
| HBIO | Harvard Bioscience, Inc. | 100.00 | 1 | ['supplier'] |
| FISI | Financial Institutions, Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 56.70 | 1 | ['customer', 'supplier'] |